Application of 5-Aminosalicylic Acid Oral Formulations and Its Combination with Traditional Chinese Medicine in Treatment of Inflammatory Bowel Disease
The derivative 5-aminosalicylic acid(5-ASA),also known as amino salicylic acid or mesalazine,is derived from natural anti-inflammatory compound salicylic acid isolated and purified from willow,and is a first-line drug for the treatment and prevention of inflammatory bowel disease(IBD)relapses.Despite the widespread clinical use of oral colon-specific 5-ASA formulations such as Salofalk,Asacol,and Pentasa in the treatment of IBD,several unmet clinical needs and formulation deficiencies persist,including premature drug release in the small intestine,significant influence by gastrointestinal physiological conditions,suboptimal efficacy in treating Crohn's disease(CD)and severe ulcerative colitis(UC),reduced mucosal microbiota diversity in UC patients,increased risk with long-term use,and decreased patient compliance.To address these issues,current research focuses on developing novel drug delivery carriers,such as silica nanoparticles and hydrogels.These carriers are designed based on multi-mechanism drug release principles,including pH-dependence,time-delay control,and microbiota/enzyme-triggered release to improve the efficacy of 5-ASA and to enhance patient tolerance and adherence to treatment.Furthermore,combining oral 5-ASA formulations with traditional Chinese medicine(TCM)therapies,such as retention enemas,oral decoctions,and injections,can synergistically enhance anti-inflammatory effects,achieving the goal of increased efficacy and reduced toxicity.This review covers the progress in the development of various oral 5-ASA formulations,recent advancements in new formulations and drug delivery carriers,and the current status of clinical applications and research on combining 5-ASA with TCM.This study is expected to provide references for the modification of 5-ASA dosage forms,research on carrier materials,and clinical use,ultimately improving treatment outcomes for IBD patients.
5-aminosalicylic acidoral colon-specific preparationdrug delivery carriercombined therapy with traditional Chinese medicineinflammatory bowel disease
万方数据
维普
